ARCHER PHARMACEUTICALS, INC.
Selective SYK negative allosteric modulator (NAM) for Alzheimer's disease treatment
Follows are private to you and power your alerts
Updated · archerpharmaceuticals.com
- Sector
- Biotech
- Headquarters
- Sarasota, FL
- Founded
- 2008
- Latest Form D
- $2.7M, Dec 2008
- Total capital
- $5.1M
- Federal grants
- $2.4M
- 3 awards · 2018–2021
- Rank in peer group#445 of 514
- Private capital raised
- $2.7M
- 1 Form D · last Dec 2008
- 215 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$699K
- Federal grantHealth and Human S · Phase II · Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$1.5M
- Federal grantHealth and Human S · Phase II · Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$225K
- Private capital raisedForm D · SEC · 1st filing$2.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Michael MullanResearcherExecutive Officer, DirectorLinked by $2.4M in grants as PI
- Fiona CrawfordExecutive OfficerNamed in SEC Form D filings
- Geoff BirkettDirectorNamed in SEC Form D filings
- Joseph ArenaExecutive OfficerNamed in SEC Form D filings
- Robert RoskampDirectorNamed in SEC Form D filings
- Steven FordDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 1- PendingModulation Of Angiogenesis By A-beta Peptide FragmentsUSPTOApplication PCTUS2009045079
Related companies, and why
- REGENOSINE INCSimilar federal contract value in Biotech · null in contracts
- Alpine BioSimilar federal contract value in Biotech · null in contracts
- Cartography BiosciencesSimilar federal contract value in Biotech · null in contracts
- Altos LabsSimilar federal contract value in Biotech · null in contracts
- Reveris TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ABALONE BIO, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .